drugset / Trial / NCT04604132
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e. with human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring fibroblast growth factor receptor 2 (FGFR2) genetic aberrations (GA).
Timeline
- Start
- 2020-10-06
- Primary completion
- 2022-11-21
- Completion
- 2022-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Derazantinib | Small molecule | 200 mg | Oral |
| Subject | Derazantinib | Small molecule | 300 mg | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |